Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Top Cited Papers
Open Access
- 23 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Albrecht von Graefes Archiv für Ophthalmologie
- Vol. 258 (6), 1149-1156
- https://doi.org/10.1007/s00417-020-04703-x
Abstract
Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy’s Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.Funding Information
- Bayer Consumer Care AG
This publication has 9 references indexed in Scilit:
- Communicating with patients with nAMD and their families during the COVID-19 pandemicAlbrecht von Graefes Archiv für Ophthalmologie, 2020
- Rational use of face masks in the COVID-19 pandemicThe Lancet Respiratory Medicine, 2020
- Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control effortsJournal of Microbiology, Immunology and Infection, 2020
- CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2020
- Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision ImpairmentJAMA Ophthalmology, 2018
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseasesAlbrecht von Graefes Archiv für Ophthalmologie, 2017
- Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006